No products in the cart.
RevMed’s Pancreatic Cancer Pill Priced Above $475K per Year
Rasonque, a RAS inhibitor, targets a protein commonly mutated in pancreatic cancers, offering…
Tag: oncology
New Drug Approved
The FDA's recent approval of Daraxonrasib marks a significant advancement in treatment…
Daraxonrasib Drug Set to Revolutionize Pancreatic Cancer
The FDA's approval of daraxonrasib marks a significant advancement in the treatment of…
AstraZeneca’s Winning Formula Over Mega-Mergers
AstraZeneca's decision to forgo a $400 billion merger with Bristol Myers Squibb signals a…
